India · Delayed Price · Currency is INR Biocon Statistics
Total Valuation
Biocon has a market cap or net worth of INR 571.04 billion. The enterprise value is 712.45 billion.
| Market Cap | 571.04B |
| Enterprise Value | 712.45B |
Important Dates
The next confirmed earnings date is Wednesday, November 4, 2026.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | Jul 3, 2026 |
Share Statistics
| Current Share Class | 1.63B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +22.59% |
| Shares Change (QoQ) | +1.77% |
| Owned by Insiders (%) | 44.91% |
| Owned by Institutions (%) | 26.64% |
| Float | 823.80M |
Valuation Ratios
The trailing PE ratio is 103.95 and the forward PE ratio is 45.16.
| PE Ratio | 103.95 |
| Forward PE | 45.16 |
| PS Ratio | 3.30 |
| PB Ratio | 1.56 |
| P/TBV Ratio | 10.93 |
| P/FCF Ratio | 291.20 |
| P/OCF Ratio | 28.64 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.51, with an EV/FCF ratio of 363.31.
| EV / Earnings | 143.84 |
| EV / Sales | 4.11 |
| EV / EBITDA | 19.51 |
| EV / EBIT | 42.33 |
| EV / FCF | 363.31 |
Financial Position
The company has a current ratio of 1.22, with a Debt / Equity ratio of 0.42.
| Current Ratio | 1.22 |
| Quick Ratio | 0.71 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 4.23 |
| Debt / FCF | 78.71 |
| Interest Coverage | 1.87 |
Financial Efficiency
Return on equity (ROE) is 1.15% and return on invested capital (ROIC) is 3.04%.
| Return on Equity (ROE) | 1.15% |
| Return on Assets (ROA) | 1.73% |
| Return on Invested Capital (ROIC) | 3.04% |
| Return on Capital Employed (ROCE) | 3.42% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 10.53M |
| Profits Per Employee | 301,149 |
| Employee Count | 16,447 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.21 |
Taxes
In the past 12 months, Biocon has paid 622.00 million in taxes.
| Income Tax | 622.00M |
| Effective Tax Rate | 13.00% |
Stock Price Statistics
The stock price has decreased by -7.23% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -7.23% |
| 50-Day Moving Average | 379.16 |
| 200-Day Moving Average | 391.02 |
| Relative Strength Index (RSI) | 45.12 |
| Average Volume (20 Days) | 142,083 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biocon had revenue of INR 173.21 billion and earned 4.95 billion in profits. Earnings per share was 3.37.
| Revenue | 173.21B |
| Gross Profit | 105.98B |
| Operating Income | 16.83B |
| Pretax Income | 4.79B |
| Net Income | 4.95B |
| EBITDA | 35.83B |
| EBIT | 16.83B |
| Earnings Per Share (EPS) | 3.37 |
Balance Sheet
The company has 38.83 billion in cash and 154.34 billion in debt, with a net cash position of -115.51 billion.
| Cash & Cash Equivalents | 38.83B |
| Total Debt | 154.34B |
| Net Cash | -115.51B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 366.22B |
| Book Value Per Share | 210.14 |
| Working Capital | 31.11B |
Cash Flow
In the last 12 months, operating cash flow was 19.94 billion and capital expenditures -17.98 billion, giving a free cash flow of 1.96 billion.
| Operating Cash Flow | 19.94B |
| Capital Expenditures | -17.98B |
| Depreciation & Amortization | 19.00B |
| Net Borrowing | -46.69B |
| Free Cash Flow | 1.96B |
| FCF Per Share | n/a |
Margins
Gross margin is 61.19%, with operating and profit margins of 9.72% and 2.86%.
| Gross Margin | 61.19% |
| Operating Margin | 9.72% |
| Pretax Margin | 2.76% |
| Profit Margin | 2.86% |
| EBITDA Margin | 20.69% |
| EBIT Margin | 9.72% |
| FCF Margin | 1.16% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 0.14%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 0.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 14.85% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.59% |
| Shareholder Yield | -22.45% |
| Earnings Yield | 0.96% |
| FCF Yield | 0.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Biocon is 440.68, which is 25.91% higher than the current price. The consensus rating is "Buy".
| Price Target | 440.68 |
| Price Target Difference | 25.91% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | 12.99% |
| EPS Growth Forecast (3Y) | 38.71% |
Stock Splits
The last stock split was on June 12, 2019. It was a forward split with a ratio of 2.
| Last Split Date | Jun 12, 2019 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |